tiprankstipranks
United Therapeutics price target raised to $400 from $360 at Argus
The Fly

United Therapeutics price target raised to $400 from $360 at Argus

Argus analyst Jasper Hellweg raised the firm’s price target on United Therapeutics (UTHR) to $400 from $360 and keeps a Buy rating on the shares. The firm is positive on the strong performance of both Tyvaso DPI and Nebulized Tyvaso, as well as other products in the company’s portfolio, the promising organ manufacturing and transplant program, and the company’s solid balance sheet, the analyst tells investors in a research note.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App